News
Sensorion Announces it Has Met Primary Endpoint for SENS-401 Phase 2a Clinical Study for Residual Hearing Preservation
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing
Sensorion Will Host a Webcast on March 14, 2024, to Announce its 2023 Annual Financial Results
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
ROCTOOL: As JEC World 2024 takes place, OLLOW integrates Roctool's new R-IDS™ technology
GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2024
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal
Median Technologies to Participate in the TD Cowen’s 44th Annual Health Care Conference
Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) (Paris:ALMDT), will be participating in the TD Cowen’s 44th Annual Health Care Conference, taking place on March 4 –
Sensorion Announces its Participation in the Leerink Partners Global Biopharma Conference
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Roctool presents a new technology at JEC World, Paris (5-7 March)
BILENDI: 2023 annual revenues: 62,7 M€, Organic growth at constant exchange rates: +4.5% in Q4, +2.7% over the full year
Median Technologies to Participate and Speak at the 2024 European Congress of Radiology (ECR), February 28 – March 3, Vienna, Austria
Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) announces today that the Company will be participating and speaking at the premier European radiology conference, the
ROCTOOL: Issue of 1,049,290 new shares in connection with the early redemption of ORNAN 2021
ABIONYX Pharma Acknowledges the Clinical Results of the Phase 3 AEGIS-II Study Evaluating the Efficacy and Safety of CSL Behring’s Human-plasma-derived apoA-I, CSL112
Access here the full press release
ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies
ROCTOOL: Reserved Capital increase of 2M€ in favor of the ENRX GROUP
Sensorion Announces a €50.5 Million Financing With Participation From New and Existing US and European Healthcare Specialist Investors
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing
Sensorion Announces the Completion of Patient Inclusion in Phase 2a Clinical Trial of SENS-401 for Residual Hearing Preservation After Cochlear Implantation
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Median Technologies Reports 2023 Revenue and Summarizes 2024 Strategic Outlook
Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) announces its 2023 revenue, outlining both its strategic outlook and key milestones for 2024.
Fredrik Brag, Chief
Sensorion Announces its Participation in the Association for Research in Otolaryngology ARO 47th Annual Midwinter Meeting
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
New Date for Median Technologies’ Webcasts: February 1st, 2024
Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) announced today that Fredrik Brag, CEO and Founder of Median Technologies, will provide a company update on February
Median Technologies to Host Two Webcasts, and Provide a Company Update on January 30, 2024
Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) (Paris:ALMDT) announced today that Fredrik Brag, CEO and Founder of Median Technologies, will provide a company
Sensorion Appoints Dr. Federico Mingozzi as Non-Executive Director to the Board of Directors
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Sensorion Announces Approval to Initiate Lead Gene Therapy Candidate SENS-501 (OTOF-GT) into a Phase 1/2 Clinical Trial in some European Countries
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
BILENDI: New AI-powered features for the research platform Bilendi Discuss
ABIONYX Pharma appoints Rob Scott, MD, as Chief Medical Officer and Head of R&D
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only recombinant
Sensorion Announces Partnership With the Institut Pasteur to Accelerate Gene Therapy Programs Targeting Hearing Disorders Has Been Extended for Five Years
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
ROCTOOL: Proposed entry of ENRX into the capital of ROCTOOL
Median Technologies Announces the Drawdown of €8.5m Corresponding to the Final Tranche of the European Investment Bank Loan
Regulatory News:
Median Technologies (Paris:ALMDT) announces that it has received approval from the European Investment Bank to draw down the final tranche of the loan granted on December 18